Cyclo(-RGDfK) TFA

Names

[ Name ]:
Cyclo(-RGDfK) TFA

[Synonym ]:
Cyclo(L-arginylglycyl-L-α-aspartyl-D-phenylalanyl-L-lysyl) trifluoroacetate (1:1)
Acetic acid, 2,2,2-trifluoro-, compd. with cyclo(L-arginylglycyl-L-α-aspartyl-D-phenylalanyl-L-lysyl) (1:1)

Biological Activity

[Description]:

Cyclo(-RGDfK) TFA is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM[1]. Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface[3].

[Related Catalog]:

Research Areas >> Cancer

Signaling Pathways >> Cytoskeleton >> Integrin

[Target]

IC50: 0.94 nM (αvβ3 integrin)[1]

[In Vitro]

Cyclo(-RGDfK) is a potent and selective inhibitor of the αvβ3 integrin and exhibits a IC50 of 0.94 nM[1]. [66Ga]DOTA-E-[c(RGDfK)]2 can be prepared with high radiochemical purity (>97%), specific activity (36-67GBq/μM), in vitro stability, and moderate protein binding. MicroPET imaging up to 24 post-injection showed contrasting tumors reflecting αvβ3-targeted tracer accumulation[2].

[References]

[1]. Simecek J, et al. Benefits of NOPO as chelator in gallium-68 peptides, exemplified by preclinical characterization of (68)Ga-NOPO-c(RGDfK). Mol Pharm. 2014 May 5;11(5):1687-95.

[2]. Lopez-Rodriguez V, et al. Preparation and preclinical evaluation of (66)Ga-DOTA-E(c(RGDfK))2 as a potential theranostic radiopharmaceutical. Nucl Med Biol. 2015 Feb;42(2):109-14.

[3]. V Lopez-Rodriguez, et al. Preparation and preclinical evaluation of (66)Ga-DOTA-E(c(RGDfK))2 as a potential theranostic radiopharmaceutical. Nucl Med Biol. 2015 Feb;42(2):109-14.

Chemical & Physical Properties

[ Molecular Formula ]:
C₂₉H₄₂F₃N₉O₉

[ Molecular Weight ]:
717.694

[ Exact Mass ]:
717.305786

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.